Which drug is best for pulmonary hypertensive crisis? new trial aims to find out
NCT ID NCT07667829
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial will compare three drugs—dopamine, norepinephrine, and epinephrine—to see which works best for people experiencing a pulmonary hypertensive crisis, a life-threatening spike in blood pressure in the lungs. The study will enroll 75 adults with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension who are hospitalized. The main goal is to see which drug reduces the risk of death within 28 days, while also monitoring side effects like irregular heartbeats.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dopamine, norepinephrine, and epinephrine
- What this could lead to
- If this trial succeeds, it could identify the safest and most effective vasopressor for managing pulmonary hypertensive crisis, potentially improving survival and reducing complications.
- What could go wrong
- This is a small, early-stage trial (75 participants) comparing existing drugs, so results may not be definitive. The study is not yet recruiting, and outcomes may not apply to all patients with pulmonary hypertension.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese Academy of Medical Sciences, Fuwai Hospital
Beijing, Beijing Municipality, 10037, China
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510180, China
-
Zhongnan Hospital of Wuhan University
Wuhan, Wuhan, 430072, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an inhaled therapy replace a daily pill for PAH?
- Can a Real-World registry improve how treprostinil is used for PAH?
- Which PAH treatment strategy works better: adding a third drug or increasing the dose?
- Lung patients may soon do rehab from home via app
- AI stethoscope aims to spot silent heart and lung disease
- Could a hormone supplement ease lung pressure in COPD?